What it is
MOTS-C stands for "mitochondrial open reading frame of the 12S rRNA-c". It is a peptide — a short chain of amino acids — and what makes it unusual is where its instructions are written. Most peptides in your body are encoded in the DNA in the cell nucleus. MOTS-C is encoded in the DNA inside mitochondria, the tiny structures within cells that turn food into usable energy. Mitochondria carry a small amount of their own DNA, separate from the rest.
MOTS-C improves how skeletal muscle handles glucose (blood sugar). That implies benefits for people with diabetes, people with obesity, and anyone over 30.
Your body makes more of it when you exercise, which is why it is described as an exercise mimetic. That means a drug or compound that mimics the beneficial physical effects of exercise on the body — providing some of the health benefits of working out without the workout. It works by switching on the same cellular pathways that exercise switches on, which makes it an option for people who cannot exercise because of some limitation.
One more thing worth stressing: your natural MOTS-C levels drop substantially as you age.
It is injected under the skin — that is what subcutaneous means.
MOTS-C is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA region of the mitochondrial genome — one of the small set of peptides transcribed from mitochondrial rather than nuclear DNA. It acts as a retrograde signal from mitochondrion to nucleus.
Its principal documented effect is improved glucose metabolism in skeletal muscle, with implications for diabetes, obesity, and anyone past 30. Expression is exercise-inducible, which is the basis of the exercise-mimetic classification: activation of the same cellular pathways training activates, without the mechanical stimulus, offering a route for populations unable to train. Endogenous levels fall substantially with age.
The dysregulation picture is explicit: abnormal MOTS-C levels are associated with defective insulin secretion, insulin resistance, or both, which in turn produces dysregulated mitochondrial fission and fusion, mitochondrial oxidative stress, and reduced systemic NAD+ (nicotinamide adenine dinucleotide, the redox cofactor central to energy metabolism). MOTS-C also interacts with and regulates numerous nuclear-genome-encoded proteins governing metabolic adaptability and age-related disease — the retrograde signalling function.
Subcutaneous, infrequent dosing: once every three or five days depending on protocol, over an 8–10 week cycle.
What it does
Its core action is on glucose metabolism in muscle, and most of what follows comes from that.
On body composition and metabolism: weight loss, faster metabolism, reduced visceral fat (the fat packed around internal organs, including fat in the liver), and less insulin resistance — insulin resistance being when the body stops responding properly to its own insulin.
On performance: improved physical performance and running capacity, and improved muscle function.
On ageing and disease: there is a long list of conditions, from cardiovascular disease and inflammation through to Alzheimer's, eye disease, and infection. Those are set out in the benefits list below.
The practical dosing instruction follows the exercise link: dose first thing in the morning on an empty stomach, or 30 to 60 minutes before exercise while fasted.
The proximate mechanism is improved skeletal-muscle glucose handling and reduced insulin resistance, from which the metabolic claims follow: weight loss, increased metabolic rate, reduced visceral and hepatic fat, and protection against metabolic disorders including NASH (non-alcoholic steatohepatitis).
Performance effects: improved physical performance and running capacity, improved muscle function — consistent with the exercise-induced expression pattern.
The broader claim set extends into cardiovascular structure and function (specifically correcting diabetes-induced cardiac abnormalities and reducing vascular calcification), ophthalmology (macular degeneration), neurology (delaying Alzheimer's), immunology (immunoregulatory effects, anti-inflammatory activity in multi-morbid age-related disease, inhibition of inflammatory pain), infectious disease (activity against bacterial infection especially MRSA, improved survival of infection and sepsis), oncology support (mitigating chemotherapy side effects), and lifespan.
The dosing instruction is worth reading mechanistically: first thing in the morning fasted, or 30–60 minutes pre-exercise fasted. The pre-exercise option treats the peptide as amplifying an exercise stimulus rather than substituting for one.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- Weight loss.Animal or lab only
- Increased metabolism.Animal or lab only
- Can help protect against metabolic disorders, for example NASH (non-alcoholic steatohepatitis), a liver disease caused by fat build-up.Animal or lab only
- Reduces visceral fat — the fat around your internal organs — including fat in the liver.Animal or lab only
- Increases life expectancy.Animal or lab only
- Useful in treating cardiovascular disease, inflammation, and ageing.Animal or lab only
- Can improve physical performance and running capacity.Animal or lab only
- Improves muscle function.Animal or lab only
- Reduces insulin resistance.Animal or lab only
- Prevents macular degeneration, an eye disease affecting central vision.Animal or lab only
- Corrects abnormal heart structure and function caused by diabetes.Animal or lab only
- Offers a significant reduction in vascular calcification — calcium building up in the walls of blood vessels.Animal or lab only
- Has immunoregulatory benefits, meaning it helps balance the immune system.Animal or lab only
- Reduces side effects caused by chemotherapy.Animal or lab only
- Delays Alzheimer's.Animal or lab only
- Anti-inflammatory benefits for people with several long-term age-related diseases at once.Animal or lab only
- Inhibits inflammatory pain.Animal or lab only
- Fights bacterial infections, especially MRSA (a strain of bacteria resistant to common antibiotics).Animal or lab only
- Increases the chance of surviving an infection and/or sepsis, which is the body's dangerous over-reaction to infection.Animal or lab only
- Weight loss.Animal or lab only
- Increased metabolic rate.Animal or lab only
- Protection against metabolic disorders including NASH.Animal or lab only
- Reduced visceral fat, including hepatic fat.Animal or lab only
- Increased life expectancy.Animal or lab only
- Utility in cardiovascular disease, inflammation, and ageing.Animal or lab only
- Improved physical performance and running capacity.Animal or lab only
- Improved muscle function.Animal or lab only
- Reduced insulin resistance.Animal or lab only
- Prevention of macular degeneration.Animal or lab only
- Correction of diabetes-induced abnormal cardiac structure and function.Animal or lab only
- Significant reduction in vascular calcification.Animal or lab only
- Immunoregulatory effects.Animal or lab only
- Mitigation of chemotherapy-induced side effects.Animal or lab only
- Delayed onset of Alzheimer's.Animal or lab only
- Anti-inflammatory benefit in multi-morbid age-related disease.Animal or lab only
- Inhibition of inflammatory pain.Animal or lab only
- Antibacterial activity, particularly against MRSA.Animal or lab only
- Increased survival of infection and/or sepsis.Animal or lab only
Reconstitution and dosing
Run an 8 to 10 week cycle, then take 4 to 5 weeks off.
Dose first thing in the morning on an empty stomach, or 30 to 60 minutes before exercise while fasted. Inject under the skin.
There are two protocols. Protocol 1 is 5 mg once every five days. Protocol 2 is 3 mg once every three days — a smaller dose more often. Each protocol has its own mixing instructions for each of the three vial sizes, and the amount of water differs, so check the vial size you actually have.
"Units" below means the marks on an insulin syringe: 100 units is 1 mL. The draw figures shown are calculated from the vial size and water volume.
8–10 week cycle, 4–5 week washout. Morning fasted dosing, or 30–60 minutes pre-exercise fasted. Subcutaneous.
Two protocols, each specified across three vial sizes:
Protocol 1 — 5 mg once every 5 days. 10 mg in 1.5 mL (6.67 mg/mL) → 75 units; 20 mg in 3 mL (6.67 mg/mL) → 75 units; 40 mg in 5 mL (8 mg/mL) → 62.5 units (rounded to 63).
Protocol 2 — 3 mg once every 3 days. 10 mg in 2 mL (5 mg/mL) → 60 units; 20 mg in 3 mL (6.67 mg/mL) → 45 units; 40 mg in 5 mL (8 mg/mL) → 37.5 units (rounded to 38).
Every draw has been recomputed from vial size and water volume and agrees with the rounded unit figures; no rounding difference exceeds 10%. Note the 10 mg vial takes a different water volume between the two protocols (1.5 mL vs 2 mL) while the 20 mg and 40 mg vials do not — so reconstitute for the protocol you intend to run, not for the vial in general.
The two protocols deliver 7 mg/week and 7 mg/week respectively on average, so they are near-equivalent in weekly exposure and differ mainly in peak-to-trough profile.
Protocol 1 — 10 mg vial (5 mg every 5 days)
Mix with 1.5 mL (150 units) of bacteriostatic water.
6.67 mg/mL · 66.67 mcg per unit
Cycle: 8–10 week cycle followed by a 4–5 week washout · Frequency: Once every 5 days; first thing in the morning on an empty stomach, or 30–60 minutes before exercise while fasted; subcutaneous
| When | Dose | Draw | How often |
|---|---|---|---|
| Whole cycle (5 mg) | 5 mg | 75 units | once every 5 days |
Protocol 1 — 20 mg vial (5 mg every 5 days)
Mix with 3 mL (300 units) of bacteriostatic water.
6.67 mg/mL · 66.67 mcg per unit
Cycle: 8–10 week cycle followed by a 4–5 week washout · Frequency: Once every 5 days; first thing in the morning on an empty stomach, or 30–60 minutes before exercise while fasted; subcutaneous
| When | Dose | Draw | How often |
|---|---|---|---|
| Whole cycle (5 mg) | 5 mg | 75 units | once every 5 days |
Protocol 1 — 40 mg vial (5 mg every 5 days)
Mix with 5 mL (500 units) of bacteriostatic water.
8 mg/mL · 80 mcg per unit
Cycle: 8–10 week cycle followed by a 4–5 week washout · Frequency: Once every 5 days; first thing in the morning on an empty stomach, or 30–60 minutes before exercise while fasted; subcutaneous
| When | Dose | Draw | How often |
|---|---|---|---|
| Whole cycle (5 mg) | 5 mg | 62.5 units | once every 5 days |
Protocol 2 — 10 mg vial (3 mg every 3 days)
Mix with 2 mL (200 units) of bacteriostatic water.
5 mg/mL · 50 mcg per unit
Cycle: 8–10 week cycle followed by a 4–5 week washout · Frequency: Once every 3 days; first thing in the morning on an empty stomach, or 30–60 minutes before exercise while fasted; subcutaneous
| When | Dose | Draw | How often |
|---|---|---|---|
| Whole cycle (3 mg) | 3 mg | 60 units | once every 3 days |
Protocol 2 — 20 mg vial (3 mg every 3 days)
Mix with 3 mL (300 units) of bacteriostatic water.
6.67 mg/mL · 66.67 mcg per unit
Cycle: 8–10 week cycle followed by a 4–5 week washout · Frequency: Once every 3 days; first thing in the morning on an empty stomach, or 30–60 minutes before exercise while fasted; subcutaneous
| When | Dose | Draw | How often |
|---|---|---|---|
| Whole cycle (3 mg) | 3 mg | 45 units | once every 3 days |
Protocol 2 — 40 mg vial (3 mg every 3 days)
Mix with 5 mL (500 units) of bacteriostatic water.
8 mg/mL · 80 mcg per unit
Cycle: 8–10 week cycle followed by a 4–5 week washout · Frequency: Once every 3 days; first thing in the morning on an empty stomach, or 30–60 minutes before exercise while fasted; subcutaneous
| When | Dose | Draw | How often |
|---|---|---|---|
| Whole cycle (3 mg) | 3 mg | 37.5 units | once every 3 days |
10 mg in 1.5 mL is 6.67 mg/mL, or 66.67 mcg per unit. Draw 75 units (0.75 mL) for 5000 mcg.
Who should avoid it
- Anyone pregnant or breastfeeding.
- Children and adolescents — it is not appropriate for them.
- Talk to a doctor before starting, and go through your full medication list with them.
- Pregnancy or breastfeeding.
- Paediatric and adolescent use.
- Note how short this list is relative to the breadth of the claims — no glycaemic, cardiac, hepatic, or oncological screening is specified despite claimed activity in all of those areas.
Side effects
- Reaction where you inject — redness, swelling, itching, bruising.
- Headache.
- Mild stomach upset.
- Mild tiredness or sluggishness, particularly in the early weeks while your body is adjusting.
- Muscle cramping.
- Do not overuse it. Very high doses, or using it for too long, may cause oxidative stress (damage from unstable molecules called free radicals), tissue fatigue, or disruption to your thyroid or cortisol rhythms — cortisol being the hormone that follows a daily cycle and helps govern your energy and stress response.
- Injection-site reaction (erythema, swelling, pruritus, bruising).
- Headache.
- Mild gastrointestinal disturbance.
- Mild fatigue or lethargy, particularly during the adaptive phase.
- Muscle cramping.
- Overuse warning: extremely high doses and/or prolonged use may produce oxidative stress or tissue fatigue, or disrupt thyroid or cortisol rhythms. That last item is the reason the protocols dose every three or five days rather than daily.
User reports
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
The strongest recommendation, and it is a sequence rather than a combination. Run 10 to 14 days of SS-31 before starting MOTS-C. The idea is that SS-31 prepares the mitochondria for what MOTS-C then does to them. These are called synergistic peptides — two peptides whose combined benefits are greater than either achieves alone.
Sequential, not concurrent: 10–14 days of SS-31 preceding MOTS-C initiation, on the rationale that SS-31 primes mitochondrial infrastructure for MOTS-C's mechanism. The SS-31 entry states the same recommendation and specifies its standard protocol for the priming course.
- Humanin
For strong anti-ageing and cell-protective effects alongside MOTS-C. Humanin is another peptide encoded in mitochondrial DNA, like MOTS-C.
The other well-characterised mitochondrial-derived peptide, paired here for anti-ageing and cytoprotective synergy.
Enhances the fat-burning and metabolic effects.
Adds a triple-reuptake-inhibitor appetite and expenditure arm to the metabolic effect. Note that compound's own extensive cardiovascular and serotonergic exclusions before combining.
This or CJC-1295 can be added for extra weight loss or for stimulating the growth hormone pathway.
An alternative to CJC-1295 for additional weight loss, via a lipolytic rather than GH-axis route.
The alternative to AOD-9604 in this pairing, for growth hormone pathway stimulation.
The GH-secretagogue option in the AOD-9604-or-CJC-1295 pairing.
This or TB-500 can be added to support performance, preserve muscle, and reduce inflammation.
Offered alongside TB-500 for performance support, muscle preservation, and inflammation reduction.
The alternative to BPC-157 in this pairing, for the same purposes.
The alternative to BPC-157 in this pairing, same stated rationale.
Glutathione or NAD+ precursors are suggested for longevity and mitochondrial support during a MOTS-C cycle. NAD+ stands for nicotinamide adenine dinucleotide, a molecule every cell needs to turn food into usable energy. Note that the suggestion is precursors — substances the body converts into NAD+ — while the entry linked here is NAD+ itself.
The suggestion specifies NAD+ precursors rather than NAD+ directly; the entry linked is the injectable NAD+ compound itself, which is the closest equivalent on this site. Rationale given is longevity and mitochondrial support during the cycle, and it connects to the observation that MOTS-C dysregulation is accompanied by reduced systemic NAD+.
- Glutathione
The alternative to NAD+ precursors in this pairing, for longevity and mitochondrial support.
The antioxidant arm of the longevity-support pairing.
Dosing figures have been reviewed and units are recomputed from the stated protocol.